Matthew Labriola

Also affiliated with Duke Medical Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types”.

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001792

N/A

4.2DataRank · unranked

115 citations

Matthew D. Tucker, Ramy Sedhom, Eric Schwartz, Jason Zhu, Chester Kao +12 more

DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.129

N/A

0DataRank · unranked

0 citations

Richard E. Green, Joseph J. Park, Olesia Kellezi, Clara Hwang, Pedro C. Barata +15 more